Congruence Therapeutics, a clinical-stage, computationally driven biotechnology company, announced on Thursday the closing of a USD39.5m financing.

The financing was co-led by new investor Dimension and existing investor OrbiMed. Additional investors included Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital's Thrive Venture Fund, Driehaus, and Silver Arc.

Congruence focuses on pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson's disease and Alpha-1 antitrypsin (A1AT) deficiency.

Proceeds from the financing will support the Phase 1/1b study of CGX-926, the company's lead programme for MC4R-deficient genetic obesity, in healthy subjects and patients with MC4R-deficiency. Congruence also plans to complete IND-enabling activities for two additional development candidates targeting GBA1-driven Parkinson's Disease and Alpha-1 antitrypsin deficiency, with the goal of filing a CTA/IND for both programmes in early 2027.

"Our mission is to translate biology, chemistry and protein structural insights into medicines that address disease at its molecular origin," said Dr. Clarissa Desjardins, Congruence Therapeutics' co-founder and CEO. "In addition to CGX-926, we are advancing multiple proprietary and collaborative programs. We thank our new and existing investors for their continued support."